Jefferies Initiates Coverage on Anthem Biosciences With Rs 1,050 Target
· Business · Economic Times
Global brokerage Jefferies has initiated coverage on Anthem Biosciences with a Buy rating and a price target of Rs 1,050, representing a potential upside of around 20% from its previous close. The valuation is set at 65 times estimated earnings per share for September 2028, reflecting a 10% premium over the sector's one-year forward average multiple. Jefferies attributes its bullish stance to the company's integrated CRDMO model, strong return ratios, and early investments in therapeutic platforms such as peptides and oligonucleotides. The brokerage forecasts an 18% revenue CAGR for Anthem between FY26 and FY29, driven by manufacturing expansion and new commercial programmes. Key risks to this outlook include customer concentration and high capital expenditure.
Why it matters
The coverage highlights growth expectations for the Indian CRDMO sector, directly impacting investors and market sentiment around Anthem Biosciences' stock performance.
Read the original report — Economic Times
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.